Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758317 | 0.89 | ELANE (0.59) | ELANENOTUMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5759735 | 0.85 | ELANE (0.57) | ELANESMN1; SMN2KMT2A | |
| SCHEMBL5759586 | 0.84 | ELANE (0.63) | ELANENOTUMCNR2KDM4EALDH1A1 | |
| SCHEMBL11895127 | 0.84 | BRD4 (0.42) | ELANEBRD4NOTUMCNR2CHRM4 | |
| SCHEMBL561083 | 0.84 | BRD4 (0.46) | ELANEBRD4NOTUMCHRM4CHRM2 | |
| SCHEMBL31490322 | 0.84 | BRD4 (0.46) | ELANEBRD4NOTUMCHRM4CHRM2 | |
| SCHEMBL5757337 | 0.84 | ELANE (0.56) | ELANENOTUM | |
| SCHEMBL5437717 | 0.84 | PLA2G10 (0.47) | ELANEBRD4CNR2CHRM4KMT2A | |
| SCHEMBL5757609 | 0.84 | ELANE (0.56) | ELANEKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5759188 | 0.82 | ELANE (0.60) | ELANENOTUMCNR2CCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885BRD4 2242/4885NOTUM 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.